Biomedicine

PharmaSurgics develops and commercialises a novel treatment for the prevention of harmful scarring (adhesions) after surgery.
PharmaSurgics core technology constitutes a patented compound with highly beneficial anti-inflammatory and anti-microbial effects that promote the healing process.

In addition, the multifunctional properties of the compound offer the potential for multiple commercialisation projects to be conducted parallel.